Biofarm S.A. Stock

BIO

ROBIOFACNOR9

Pharmaceuticals

End-of-day quote Bucharest S.E. 2026-08-24			5-day change	1st Jan Change
1.370 ^RON	+0.74%		-.--%	+69.14%

08-14	Biofarm S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-23	Polpharma SA Pharmaceutical Works completed the acquisition of Biofarm S.A. from Longshield Investment Group SA, Lion Capital S.A. and other shareholders.	CI

Biofarm SA is a Romania-based company engaged in the pharmaceutical sector. The Company focuses on the production and marketing of pharmaceutical preparations. The Company is active in the manufacture and wholesale of over the counter drugs, prescription medications and dietary supplements. The Companyâ€™s product portfolio includes pharmaceutical preparations for digestive system, musculoskeletal system, immune stimulation, respiratory system, cold and flu symptoms and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants and cosmetics, among others. Additionally, the Company offers services, such as consultancy on Romanian pharmaceutical market, manufacturing of non-sterile products, the investment in research, promotion and packaging. The main shareholder of the Company is Societatea de Investitii Financiare Muntenia SA.

Employees

374

Sector

Pharmaceuticals

Calendar

11-12

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	1.35B 284M 252M 236M 215M 405M 27.37B 411M 2.86B 1.11B 13.94B 1.07B 1.04B 44.77B	P/E 2024	10.4x	P/E 2025	8.79x
Enterprise Value	1.18B 249M 221M 207M 188M 354M 23.94B 359M 2.5B 967M 12.19B 934M 913M 39.16B	EV / Sales 2024	2.03x	EV / Sales 2025	1.97x
Free-Float	7.26%	Yield 2024	4.34%	Yield 2025	5.19%

Markets		Quality
Bucharest S.E.	BIO	End-of-day quote
Deutsche Boerse AG	H3D	Delayed

08-14	Biofarm S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-23	Polpharma SA Pharmaceutical Works completed the acquisition of Biofarm S.A. from Longshield Investment Group SA, Lion Capital S.A. and other shareholders.	CI
05-05	Biofarm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-05	Polpharma SA Pharmaceutical Works proposed to acquire Biofarm S.A. from Longshield Investment Group SA, Lion Capital S.A. and other shareholders for RON 1.4 billion.	CI
03-23	Biofarm S.A. announces Annual dividend, payable on May 29, 2026	CI
02-26	Biofarm S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-14	Biofarm S.A. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-08-13	Biofarm S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-05-13	Biofarm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-20	Biofarm S.A. announces Annual dividend, payable on September 05, 2025	CI
25-02-27	Biofarm S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-11-13	Biofarm S.A. Reports Earnings Results for the Nine Months Ended September 30, 2024	CI
24-08-21	Biofarm S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI

01-12	Biofarm S A : 2026-01-12 Current Report Evaluation of strategic options regarding the development of the Company	PU
11-28	Biofarm S A : 2025-11-28 Current Report	PU
11-14	Biofarm S A : 2025-09-30 Administrator Report - IFRS Financial Statements	PU
11-14	Biofarm S A : 2025-11-14 Communique	PU
11-12	Biofarm S A : 2025-11-12 Current Report	PU

1 day	+0.74%
3 months	+0.37%
6 months	+12.30%
Current year	+69.14%

Biofarm S.A. Stock

Stocks

BIO

ROBIOFACNOR9

Pharmaceuticals

Valuation: Biofarm S.A.

Chart: Biofarm S.A.

Latest news: Biofarm S.A.

Press Releases: Biofarm S.A.

Quotes and Performance

Price Extremes

Managers and Directors: Biofarm S.A.

Generic Pharmaceuticals

Financials

Company Profile

Current year	0.81	1.5
1 year	0.78	1.5
3 years	0.62	1.5
5 years	0.53	1.5
10 years	0.26	1.5

Manager	Title	Age	Since
Catalin Vicol CEO	Chief Executive Officer	51	2018-11-14
Mihai Zoescu DFI	Director of Finance/CFO	46	2021-01-17
Mirel Florica COO	Chief Operating Officer	-	2023-08-31

Director	Title	Age	Since
Andrei Hrebenciuc CHM	Chairman	42	2018-12-30
Bogdan-Alexandru Dragoi BRD	Director/Board Member	46	2015-12-09
Catalin Vicol BRD	Director/Board Member	51	2018-11-14

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOFARM S.A.	+0.74%	-.--%	+69.14%	+76.55%	284M
ELI LILLY AND COMPANY	-0.62%	-2.71%	+39.30%	+114.07%	1,025B
JOHNSON & JOHNSON	-2.30%	-4.44%	+39.03%	+66.07%	623B
ABBVIE INC.	-0.63%	-1.96%	+6.36%	+74.38%	459B
MERCK & CO., INC.	-1.03%	-2.82%	+59.56%	+39.69%	355B
ROCHE HOLDING AG	-0.27%	-3.47%	+22.34%	+40.21%	336B
NOVARTIS AG	-0.47%	-1.90%	+12.98%	+25.86%	270B
ASTRAZENECA PLC	+0.03%	-4.24%	-3.48%	+9.77%	247B
AMGEN INC.	-3.38%	+0.30%	+36.44%	+51.54%	220B
GILEAD SCIENCES, INC.	-1.04%	-1.46%	+32.70%	+96.82%	183B
Average	-0.13%	-1.48%	+31.44%	+59.50%	371.85B
Weighted average by Cap.	+0.12%	-2.11%	+30.35%	+69.47%

	2024	2025
Net sales	287M 60.39M 53.64M 50.16M 45.71M 86.06M 5.81B 87.24M 607M 235M 2.96B 227M 222M 9.51B	319M 67.25M 59.73M 55.86M 50.9M 95.83M 6.47B 97.14M 676M 262M 3.3B 252M 247M 10.59B
Net income	74.4M 15.67M 13.92M 13.01M 11.86M 22.33M 1.51B 22.63M 157M 60.94M 768M 58.82M 57.55M 2.47B	101M 21.19M 18.82M 17.6M 16.04M 30.2M 2.04B 30.61M 213M 82.43M 1.04B 79.56M 77.84M 3.34B
Net Debt	-123M -25.87M -22.97M -21.49M -19.58M -36.86M -2.49B -37.37M -260M -101M -1.27B -97.12M -95.01M -4.07B	-169M -35.61M -31.63M -29.58M -26.96M -50.75M -3.43B -51.45M -358M -139M -1.75B -134M -131M -5.61B